Colorectal cancer in patients seen at the teaching hospitals of Guadeloupe and Martinique: discrepancies, similarities in clinicopathological features, and p53 status

被引:6
作者
Decastel, Monique [1 ,9 ]
Ossondo, Marlene [2 ]
Andrea, Anne-Marie [3 ]
Tressieres, Benoit [4 ]
Veronique-baudin, Jacqueline [5 ]
Deloumeaux, Jacqueline [6 ]
Lubeth, Marc [7 ]
Smith-ravin, Juliette [8 ]
机构
[1] UAG, CNRS SNC 9169, UMR Inserm S1134, Pointe A Pitre, Guadeloupe, France
[2] Teaching Hosp Zobda Quitman, Dept Anatomopathol, Fort De France, Martinique, France
[3] Teaching Hosp Pointe A Pitre, Dept Anatomopathol, Pointe A Pitre, Guadeloupe, France
[4] Teaching Hosp Pointe A Pitre, Ctr Invest Clin EC Antilles Guyane, CIE 802 Inserm, Pointe A Pitre, Guadeloupe, France
[5] AMREC, Canc Registry Martinique, Fort De France, Martinique, France
[6] Teaching Hosp Pointe A Pitre, Canc Registry Guadeloupe, Pointe A Pitre, Guadeloupe, France
[7] Teaching Hosp Pointe A Pitre, Dept Digest Surg, Pointe A Pitre, Guadeloupe, France
[8] UAG, Dept Sci Interfac, AIHP GEODE BIOSPHERES EA929, F-97200 Fort De France, Martinique, France
[9] CHU Pointe A Pitre, UMR S 1134 Inserm, F-97159 Pointe A Pitre, Guadeloupe, France
关键词
Colorectal cancer; Guadeloupian patients; Martinican patients; Clinicopathology; p53; status; Discrepancy;
D O I
10.1186/1472-6890-14-12
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In Guadeloupe and Martinique, two French Overseas Departments, colorectal cancer (CRC) has become an essential public health issue. However, little is known about CRC characteristics and the p53 status in these populations, particularly in Guadeloupe, whereas certification of a cancer registry has been recently validated. Methods: This was a descriptive retrospective study of 201 patients who, between 1995 and 2000, underwent surgery for CRC in the Guadeloupe Teaching Hospital (GlpeTH; 83 patients) and in the Martinique Teaching Hospital (MqueTH; 118 patients). The clinicopathological features and the p53 expression, evaluated with immunohistochemistry, were compared at the time of diagnosis. A relationship between these parameters and the p53 expression was also studied. Data were analysed, using the SPSS computer software version 17.0. Results: No statistical difference was found between the two groups of patients regarding age (p = 0.60), percentage of young patients (<= 50 years; p = 0.94)), sex (p = 0.47), histological type (p = 0.073) and tumour sites (p = 0.65), although the GlpeTH patients were diagnosed with more distal colon cancers (54.2%) than the Mque TH patients (47.4%). By contrast, a significant difference was found regarding the tumour grade (p < 0.0001), the pTNM stage (p = 0.045) and the pT stage (p < 0.0001). Regarding p53 expression, solely for the MqueTH patients, nuclear expression was associated with pTNM, the percentage of p53 negative tumours increasing with the progression of the pTNM stages (p = 0.029). Conclusions: For the first time, this study reveals discrepancies in clinicopathological features and in the p53 status between the two groups of patients. The GlpeTH patients were diagnosed with more moderated CRCs but with few CRCs at pTNM IV stage. By contrast, the MqueTH patients were diagnosed with more differentiated tumours, but with many more CRCs at pTNM IV stage. This paradox may be due to differences in tumour location (distal vs proximal), multiplicity of the genetic profiles of patients, or patients getting treatment elsewhere. Although our study is limited due to its small size, it emphasizes the originality of our results.
引用
收藏
页数:8
相关论文
共 32 条
[1]   Survival of cancer patients in France:: A population-based study from the Association of the French Cancer Registries (FRANCIM) [J].
Bossard, N. ;
Velten, M. ;
Remontet, L. ;
Belot, A. ;
Maarouf, N. ;
Bouvier, A. M. ;
Guizard, A. V. ;
Tretarre, B. ;
Launoy, G. ;
Colonna, M. ;
Danzon, A. ;
Molinie, F. ;
Troussard, X. ;
Bourdon-Raverdy, N. ;
Carli, P. M. ;
Jaffre, A. ;
Bessaguet, C. ;
Sauleau, E. ;
Schvartz, C. ;
Arveux, P. ;
Maynadie, M. ;
Grosclaude, P. ;
Esteve, J. ;
Faivre, J. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (01) :149-160
[2]   Clinicopathological patterns and challenges of management of colorectal cancer in a resource-limited setting: a Tanzanian experience [J].
Chalya, Phillipo L. ;
Mchembe, Mabula D. ;
Mabula, Joseph B. ;
Rambau, Peter F. ;
Jaka, Hyasinta ;
Koy, Mheta ;
Mkongo, Eliasa ;
Masalu, Nestory .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2013, 11
[3]   Colorectal cancer in France [J].
Chevreul, Karine .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2010, 10 :15-20
[4]  
Dieye M, 2011, I VEILLE SANITAIRE I, V8, P1
[5]   Cancer incidence in Martinique: a model of epidemiological transition [J].
Dieye, Moustapha ;
Veronique-Baudin, Jacqueline ;
Draganescu, Cyprian ;
Azaloux, Herve .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2007, 16 (02) :95-101
[6]  
Diez M, 2000, ANTICANCER RES, V20, P3907
[7]   Determination of molecular marker expression can predict clinical outcome in colon carcinomas [J].
Galizia, G ;
Lieto, E ;
Ferraraccio, F ;
Orditura, M ;
De Vita, F ;
Castellano, P ;
Imperatore, V ;
Romano, C ;
Ciardiello, F ;
Agostini, B ;
Pignatelli, C .
CLINICAL CANCER RESEARCH, 2004, 10 (10) :3490-3499
[8]   ACTIVATING MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT - A MONOCLONAL-ANTIBODY SPECIFIC FOR THE MUTANT FORM [J].
GANNON, JV ;
GREAVES, R ;
IGGO, R ;
LANE, DP .
EMBO JOURNAL, 1990, 9 (05) :1595-1602
[9]   Epidemiology and prevention of colorectal cancer [J].
Hawk, ET ;
Limburg, PJ ;
Viner, JL .
SURGICAL CLINICS OF NORTH AMERICA, 2002, 82 (05) :905-+
[10]   TP53 mutation in colorectal cancer [J].
Iacopetta, B .
HUMAN MUTATION, 2003, 21 (03) :271-276